002603 以岭药业
已收盘 03-13 15:00:00
资讯
新帖
简况
以岭药业(002603.SZ)：泊马度胺化学原料药上市申请获批准
智通财经 · 03-03
以岭药业(002603.SZ)：泊马度胺化学原料药上市申请获批准
以岭药业：公司子公司有部分健康绿农产品
证券之星 · 03-03
以岭药业：公司子公司有部分健康绿农产品
以岭药业（002603）披露全资子公司仲裁事项公告，3月2日股价下跌2.4%
证券之星 · 03-02
以岭药业（002603）披露全资子公司仲裁事项公告，3月2日股价下跌2.4%
以岭药业荣膺“王者之舟·最爱人才雇主”奖
证券之星 · 02-09
以岭药业荣膺“王者之舟·最爱人才雇主”奖
以岭药业：公司现有17个专利中药新药均按规修订说明书
证券之星 · 02-04
以岭药业：公司现有17个专利中药新药均按规修订说明书
1月26日以岭药业涨7.90%，汇添富中证中药ETF基金重仓该股
证券之星 · 01-26
1月26日以岭药业涨7.90%，汇添富中证中药ETF基金重仓该股
以岭药业：芪苈强心胶囊显著降低主要复合终点事件发生风险22%
证券之星 · 01-23
以岭药业：芪苈强心胶囊显著降低主要复合终点事件发生风险22%
以岭药业：公司旗下子公司健康科技直播间未直播销售此类产品
证券之星 · 01-23
以岭药业：公司旗下子公司健康科技直播间未直播销售此类产品
以岭药业（002603）披露2025年度业绩预告，1月22日股价上涨0.94%
证券之星 · 01-22
以岭药业（002603）披露2025年度业绩预告，1月22日股价上涨0.94%
以岭药业：预计2025年净利润为12亿元—13亿元
新京报 · 01-22
以岭药业：预计2025年净利润为12亿元—13亿元
以岭药业连续五年荣膺“中国年度最佳雇主-石家庄最佳雇主”
证券之星 · 01-15
以岭药业连续五年荣膺“中国年度最佳雇主-石家庄最佳雇主”
【重磅】以岭药业1类新药亮相！猛攻超800亿市场
证券之星 · 01-09
【重磅】以岭药业1类新药亮相！猛攻超800亿市场
以岭药业（002603）披露全资孙公司收到化学原料药上市申请批准通知书，1月7日股价上涨0.45%
证券之星 · 01-07
以岭药业（002603）披露全资孙公司收到化学原料药上市申请批准通知书，1月7日股价上涨0.45%
以岭药业入选“2025中国企业ESG百强”榜单
新浪财经 · 01-07
以岭药业入选“2025中国企业ESG百强”榜单
以岭药业(002603.SZ)：盐酸伐昔洛韦片取得药品注册证书
智通财经 · 01-07
以岭药业(002603.SZ)：盐酸伐昔洛韦片取得药品注册证书
以岭药业创新药益肾养心安神片被北京晚报评为家庭常备安神助眠用药
证券之星 · 01-05
以岭药业创新药益肾养心安神片被北京晚报评为家庭常备安神助眠用药
以岭药业以创新与社会责任诠释领军担当荣获“年度医药行业领军企业”
证券之星 · 01-04
以岭药业以创新与社会责任诠释领军担当荣获“年度医药行业领军企业”
以岭药业斩获全国首个酸枣仁GAP基地
证券之星 · 2025-12-31
以岭药业斩获全国首个酸枣仁GAP基地
流感疫情持续，防控系统工程再受考验
证券之星 · 2025-12-31
流感疫情持续，防控系统工程再受考验
以岭药业获第十四届金融界“金智奖”杰出投资者关系（IR）团队奖
证券之星 · 2025-12-27
以岭药业获第十四届金融界“金智奖”杰出投资者关系（IR）团队奖
暂无数据
公司概况
公司名称：
石家庄以岭药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-07-28
主营业务：
石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊和芪苈强心胶囊。公司先后多次承担国家及省部级科研计划项目，荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。
发行价格：
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":16.92,"timestamp":1773385434000,"preClose":16.95,"halted":0,"volume":9083311,"delay":0,"changeRate":-0.0018,"floatShares":1377000000,"shares":1671000000,"eps":-0.167,"marketStatus":"已收盘","change":-0.03,"latestTime":"03-13 15:00:00","open":16.88,"high":16.98,"low":16.85,"amount":154000000,"amplitude":0.0077,"askPrice":16.93,"askSize":605,"bidPrice":16.92,"bidSize":1367,"shortable":0,"etf":0,"ttmEps":-0.167,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":5,"adr":0,"adjPreClose":16.95,"symbolType":"stock","openAndCloseTimeList":[[1773365400000,1773372600000],[1773378000000,1773385200000]],"highLimit":18.65,"lowLimit":15.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.65,"roa":"--","roe":"9.34%","epsLYR":-0.4337,"committee":0.190809,"marketValue":28268000000,"turnoverRate":0.0066,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-16。","floatMarketCap":23296000000},"requestUrl":"/m/hq/s/002603/tweets","defaultTab":"tweets","newsList":[{"id":"2616687317","title":"以岭药业(002603.SZ)：泊马度胺化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616687317","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616687317?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:41","pubTimestamp":1772527260,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)公告，公司全资孙公司万洋衡水制药有限公司(简称“衡水万洋”)收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，由衡水万洋提交的“泊马度胺”化学原料药上市申请已获批准。据公告信息，泊马度胺是第3代免疫调节剂，具有免疫调节、抗血管生成和抗肿瘤作用，对多种恶性血液疾病有效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"以岭药业(002603.SZ)：泊马度胺化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002603","BK0042","BK0097","BK0239","BK0046"],"gpt_icon":0},{"id":"2616395564","title":"以岭药业：公司子公司有部分健康绿农产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2616395564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616395564?lang=zh_cn&edition=full","pubTime":"2026-03-03 09:16","pubTimestamp":1772500579,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业(002603)03月02日在投资者关系平台上答复投资者关心的问题。投资者提问：观察公司很久了，觉得我们公司很适合制造织布机或者发展绿色环保食品，公司管理层有无以上计划？以岭药业回复：投资者您好，公司子公司故城县茂丰农业科技开发有限公司有部分健康绿农产品。公司目前暂无您提及的相关机器制造业务计划，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300007672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0046","000061","BK0028","BK0016","BK0097","BK0210","002603","BK0027","BK0042"],"gpt_icon":0},{"id":"2616353934","title":"以岭药业（002603）披露全资子公司仲裁事项公告，3月2日股价下跌2.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616353934?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:20","pubTimestamp":1772461233,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，以岭药业报收于17.06元，较前一交易日下跌2.4%，最新总市值为285.02亿元。近日，石家庄以岭药业股份有限公司披露《关于全资子公司仲裁事项的公告》。公告显示，公司全资子公司以岭万洲国际制药有限公司收到香港国际仲裁中心仲裁受理通知，Gerbera Therapeutics, Inc.因委托加工其美国医药产品相关协议履行争议，主张以岭万洲未充分履行协议并要求赔偿损失。案件已由HKIAC受理，尚未组成仲裁庭，未开庭审理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200039711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002603","BK0097","BK0042","BK0188","BK0046"],"gpt_icon":0},{"id":"2610682454","title":"以岭药业荣膺“王者之舟·最爱人才雇主”奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2610682454","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610682454?lang=zh_cn&edition=full","pubTime":"2026-02-09 15:43","pubTimestamp":1770623031,"startTime":"0","endTime":"0","summary":"近日，在BOSS直聘“一起生长·ECHO2026”年度合作伙伴大会上，以岭药业荣获2026年度“王者之舟·最爱人才雇主”奖项。该奖项完全基于2025年度平台用户真实行为数据产生，客观反映了企业在招聘市场中获得的广泛认可与综合吸引力。以岭药业始终将人才建设置于企业发展的重要位置，致力于构建全方位的人才发展体系。此次获奖，是以岭药业人才建设的新起点，更是一份持续前行的责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026020900014880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0046","002603","BK0097","BK0188"],"gpt_icon":0},{"id":"2608820793","title":"以岭药业：公司现有17个专利中药新药均按规修订说明书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608820793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608820793?lang=zh_cn&edition=full","pubTime":"2026-02-04 09:06","pubTimestamp":1770167184,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业(002603)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问关于中药的新规:说明书上面禁忌不能写尚不明确，对公司的影响大吗？涉及的药品种类多吗？对以后的业绩会有影响吗？谢谢！以岭药业回复：投资者您好，公司现有17个专利中药新药，均在2020年底以前已按照国家药监局规定的注册程序，对药品说明书进行了修订，说明书中的【禁忌】【不良反应】【注意事项】三项均有明确表述，符合相关规定。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400007766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0097","002603","BK0042","BK0188"],"gpt_icon":0},{"id":"2606196297","title":"1月26日以岭药业涨7.90%，汇添富中证中药ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606196297","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606196297?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:49","pubTimestamp":1769413772,"startTime":"0","endTime":"0","summary":"证券之星消息，1月26日以岭药业涨7.90%，收盘报20.08元，换手率6.34%，成交量87.24万手，成交额17.08亿元。重仓以岭药业的公募基金请见下表：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为21.32。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为汇添富基金的汇添富中证中药ETF。汇添富中证中药ETF目前规模为24.52亿元，最新净值1.0639，较上一交易日上涨0.4%，近一年上涨2.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0239","002603","560080","159647","BK0046","BK0042"],"gpt_icon":0},{"id":"2605420920","title":"以岭药业：芪苈强心胶囊显著降低主要复合终点事件发生风险22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605420920","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605420920?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:33","pubTimestamp":1769157192,"startTime":"0","endTime":"0","summary":"该研究在大陆及香港地区133家医院进行，共纳入3110例HFrEF患者，研究结果证实，与对照组相比，芪苈强心胶囊联合标准化治疗显著降低主要复合终点事件发生风险22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300024577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0188","002603","BK0239","BK0097"],"gpt_icon":0},{"id":"2605642090","title":"以岭药业：公司旗下子公司健康科技直播间未直播销售此类产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2605642090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605642090?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:31","pubTimestamp":1769157077,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业(002603)01月23日在投资者关系平台上答复投资者关心的问题。投资者提问：有位说是总经理助理的刘姓女人（自称刘总）以企业为背影进行直播带货，有公司的辅Q10，新疆的特产，饱子粉，铁皮石斛等各种保健品。能说会道。是真有其人吗？还是利用上市公司直播带货？以岭药业回复：投资者您好，经核实，公司旗下子公司健康科技直播间未直播销售此类产品，你可提供具体平台及直播间等相关信息给我们。此外，公司健康产品品类有辅Q10，但不涉及您提及的其他产品。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300024389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0188","BK0097","BK0046","002603"],"gpt_icon":0},{"id":"2605849273","title":"以岭药业（002603）披露2025年度业绩预告，1月22日股价上涨0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605849273","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605849273?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:14","pubTimestamp":1769091254,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，以岭药业报收于18.33元，较前一交易日上涨0.94%，最新总市值为306.24亿元。该股当日开盘18.19元，最高18.44元，最低18.08元，成交额达4.35亿元，换手率为1.72%。公司近日发布2025年度业绩预告，预计2025年1-12月归属于上市公司股东的净利润为盈利120,000万元至130,000万元，上年同期为亏损72,451.56万元，实现扭亏为盈。业绩变动主要因营业收入恢复性增长及成本控制加强，提升利润率。本次业绩预告未经审计，最终数据以2025年年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0239","BK0188","BK0046","BK0097","BK0042"],"gpt_icon":0},{"id":"2605462023","title":"以岭药业：预计2025年净利润为12亿元—13亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462023","media":"新京报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462023?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:20","pubTimestamp":1769077200,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 1月22日，以岭药业公告，预计2025年度净利润为12亿元—13亿元，上年同期亏损7.25亿元。公司全面强化预算管理，建立全链条成本控制体系，实现提质增效，利润率水平提升明显。编辑 王进雨","market":"hk","thumbnail":"https://media.bjnews.com.cn/cover/2026/01/22/5678455820493336283.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/01/22/5678455820493336283.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1769073718129303.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1769073718129303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["002603"],"gpt_icon":0},{"id":"2603679776","title":"以岭药业连续五年荣膺“中国年度最佳雇主-石家庄最佳雇主”","url":"https://stock-news.laohu8.com/highlight/detail?id=2603679776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603679776?lang=zh_cn&edition=full","pubTime":"2026-01-15 15:15","pubTimestamp":1768461307,"startTime":"0","endTime":"0","summary":"近日，在智联招聘联合北京大学社会调查研究中心、北京大学国家发展研究院等多家专业机构共同举办的“中国年度最佳雇主”评选中，以岭药业再次凭借其卓越的人才管理体系，荣获“2025中国年度最佳雇主-石家庄最佳雇主”称号。至此，以岭药业已成功实现该项权威荣誉的“五连冠”。展望未来，以岭药业将继续秉承“继承创新，造福人类”的企业宗旨，持续优化人才战略，构建更具韧性、更富创新力的组织体系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026011500019414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0188","002603","BK0097","BK0046"],"gpt_icon":0},{"id":"2602310178","title":"【重磅】以岭药业1类新药亮相！猛攻超800亿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2602310178","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602310178?lang=zh_cn&edition=full","pubTime":"2026-01-09 09:57","pubTimestamp":1767923833,"startTime":"0","endTime":"0","summary":"今日，以岭药业的中药1.1类新药芪龙定喘片提交IND获受理。据悉，该药拟用于慢性阻塞性肺疾病稳定期心肺气虚、痰瘀阻滞证。芪龙定喘片是以岭药业2026年首款申报IND的创新药。米内网数据显示，2023-2024年中国三大终端六大市场呼吸系统疾病中成药销售额均超过800亿元，2025年前三季度超过500亿元。此外，化药1类新药G201-Na胶囊申报IND且获批临床，目前已步入II期临床，可在辅助生殖技术中，用于控制性超促排卵治疗的患者，防止提前排卵。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026010900009615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","002603","BK0188","BK0046","BK0042"],"gpt_icon":0},{"id":"2601760088","title":"以岭药业（002603）披露全资孙公司收到化学原料药上市申请批准通知书，1月7日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601760088","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601760088?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:36","pubTimestamp":1767778594,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，以岭药业报收于17.71元，较前一交易日上涨0.45%，最新总市值为295.88亿元。近日，石家庄以岭药业股份有限公司全资孙公司万洋衡水制药有限公司收到国家药品监督管理局下发的化学原料药上市申请批准通知书，其提交的达格列净化学原料药上市申请已获批准。达格列净为SGLT-2抑制剂，用于治疗2型糖尿病，具有肾脏保护和心血管获益优势。该原料药已纳入第十一批国家集采目录，降价幅度超90%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700027317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","002603","BK0046","BK0097","BK0188"],"gpt_icon":0},{"id":"2601768608","title":"以岭药业入选“2025中国企业ESG百强”榜单","url":"https://stock-news.laohu8.com/highlight/detail?id=2601768608","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601768608?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:17","pubTimestamp":1767777420,"startTime":"0","endTime":"0","summary":" 近日，新浪财经重磅发布“2025中国企业ESG百强”榜单，凭借在环境、社会、治理领域的系统性卓越实践，以岭药业成功上榜。 历经30余年稳健发展，以岭药业构建起“理论—临床—新药—产业—教学”五位一体的的独特运营模式，为企业ESG实践筑牢坚实根基。评级体系基于企业可持续发展报告及第三方数据等，纳入150余项ESG指标，得到企业ESG综合评级得分。排名位列前100的企业入选“上市公司年度ESG百强榜”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-07/doc-inhfnqzp4656836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159717","BK0046","BK0239","BK0042","002603","BK0188","BK0097","ESG"],"gpt_icon":0},{"id":"2601878784","title":"以岭药业(002603.SZ)：盐酸伐昔洛韦片取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601878784","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601878784?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:24","pubTimestamp":1767774250,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)公告，公司的全资子公司以岭万洲国际制药有限公司(简称“以岭万洲”)向国家药品监督管理局药品审评中心申报的盐酸伐昔洛韦片的上市许可申请，获得国家药品监督管理局的批准，取得药品注册证书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"以岭药业(002603.SZ)：盐酸伐昔洛韦片取得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","BK0042","BK0188","BK0046","BK0239","002603"],"gpt_icon":0},{"id":"2601075719","title":"以岭药业创新药益肾养心安神片被北京晚报评为家庭常备安神助眠用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2601075719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601075719?lang=zh_cn&edition=full","pubTime":"2026-01-05 09:46","pubTimestamp":1767577599,"startTime":"0","endTime":"0","summary":"12月31日，由《北京晚报》主办的“2025年度健康行业卓越品牌暨家庭常备药品/器械推选活动”系列榜单发布，以岭药业创新专利药物益肾养心安神片获评“2025北京晚报读者推荐家庭常备安神助眠用药”。据了解，《北京晚报》已连续十四年举办家庭常备药盘点活动。2025家庭常备药系列活动自11月启动以来，众多热心读者踊跃参与并分享意见建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026010500005007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0046","BK0239","BK1574","BK0042","002603","BK0188","BK0097","BK1161","06978"],"gpt_icon":0},{"id":"2600704310","title":"以岭药业以创新与社会责任诠释领军担当荣获“年度医药行业领军企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2600704310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600704310?lang=zh_cn&edition=full","pubTime":"2026-01-04 11:04","pubTimestamp":1767495840,"startTime":"0","endTime":"0","summary":"在财经网2025年度新消费·新经济评选中，以岭药业荣获“年度医药行业领军企业”称号。作为中药现代化领军企业，以岭药业承担着一项特殊的时代责任：推动中医药突破文化隔阂，以国际公认的科学语言走向世界。这是对学科发展的责任，是对行业信心的提振，更是对中国智慧贡献全球健康事业的积极推动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026010400000375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0188","161912","002603","BK0097","BK0239","BK0046"],"gpt_icon":0},{"id":"2595778461","title":"以岭药业斩获全国首个酸枣仁GAP基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778461?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:05","pubTimestamp":1767175521,"startTime":"0","endTime":"0","summary":"12月30日，河北省药品监督管理局发布《河北省药品监督管理局中药材GAP延伸检查结果公告》，以岭药业酸枣仁种植基地通过河北省药监局组织的GAP延伸检查，综合评定符合要求。这是全国第一个通过GAP延伸检查的酸枣仁基地。以岭药业建设酸枣仁规范化种植基地4760亩，野生抚育基地3200.49亩，基地位于河北省邢台市内丘县南赛乡。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100033663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK0042","BK0097","BK0239","BK0046"],"gpt_icon":0},{"id":"2595127727","title":"流感疫情持续，防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末，全国流感疫情持续处于高流行水平。产业链协同响应，构建多层次供应保障流感防控是一项系统工程，需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中，上市药企正通过全产业链布局，搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示，金振口服液四季度市场需求回暖，正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批，其在儿科领域的应用场景进一步拓宽。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","300244","603858","BK0074","BK0046","002603","BK0187","600079","BK0060","002393","BK0010","BK0096","BK0077","BK0097","301207","600566","000623","688276","SG9999001069.SGD","600557","BK0183","300937","BK0201","BK0070","BK0146","BK0186","BK0028","BK0239","BK0185","BK0175","BK0012","000999","BK0236","BK0042","BK0197","603882","002317","BK0284","BK0086","002728","BK0164","BK0250","BK0114","BK0188","000756"],"gpt_icon":0},{"id":"2594111822","title":"以岭药业获第十四届金融界“金智奖”杰出投资者关系（IR）团队奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2594111822","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594111822?lang=zh_cn&edition=full","pubTime":"2025-12-27 10:00","pubTimestamp":1766800813,"startTime":"0","endTime":"0","summary":"作为大会备受关注的重要成果，第十四届“金智奖”年度评选结果正式揭晓，以岭药业荣获“杰出投资者关系团队奖”。从公开信息来看，以岭药业IR团队的相关实践与上述评选标准高度契合。以岭药业此次获奖，被视为资本市场对其投资者关系管理专业性、合规性及有效性的认可，也为中药创新领域上市公司的投资者关系管理实践提供了参考样本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025122700002984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","002603","BK0046","BK0097","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773428635215,"stockEarnings":[{"period":"1week","weight":0.0095},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0009},{"period":"1year","weight":0.2245},{"period":"ytd","weight":-0.0088}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0088},{"period":"3month","weight":0.053},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.2193},{"period":"ytd","weight":0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"152746人(较上一季度减少10.22%)","perCapita":"9013股","listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","registeredCapital":"167070万元","survey":" 石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊和芪苈强心胶囊。公司先后多次承担国家及省部级科研计划项目，荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。","listedPrice":34.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}